文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

体外心肺复苏(ECPR)治疗难治性心脏骤停的成本效益:系统综述

The cost-effectiveness of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest: A systematic review.
PubMed 文献 · Resuscitation · 2025-09-16
一句话结论系统综述显示ECPR在部分场景下可能具有成本效益,但各研究间成本效益结果差异显著,与研究方法、生存假设和支付意愿阈值不同有关。

该系统综述检索MEDLINE ALL、EMBASE、Tufts CEA注册库和Web of Science至2025年2月3日,纳入15项评估成人难治性心脏骤停ECPR成本效益的经济学评价。12项(80%)报告ECPR具有成本效益的概率高,1项(7%)概率低,1项(7%)提示可能具有成本效益,1项(7%)认为无成本效益可能,后者专门评估急性主动脉夹层患者。调整后增量成本效益比(ICER)范围为2,564至276,307美元;采用美国支付意愿阈值(150,000美元)时10项研究显示ECPR仍具成本效益,采用替代阈值(40,000美元)时7项研究仍具成本效益。作者认为ECPR在某些场景下可能具有成本效益,但报告结果差异显著,亟需标准化报告。

要点

  • 15项研究中12项(80%)报告ECPR具有成本效益的概率高,1项(7%)概率低,1项(7%)提示可能具有成本效益,1项(7%)认为无成本效益可能。
  • 调整后ICER范围为2,564至276,307美元;采用美国支付意愿阈值(150,000美元)时10项研究显示ECPR仍具成本效益,采用替代阈值(40,000美元)时7项研究仍具成本效益。
  • 唯一报告无成本效益可能的研究专门评估急性主动脉夹层患者。
  • 作者结论:ECPR在某些场景下可能具有成本效益,但各研究间结果差异显著,反映方法学、生存假设和支付意愿阈值不同。
  • 作者指出该领域经济评价异质性大,亟需标准化报告以指导ECPR在不同医疗场景中的实施。

适用人群与场景

  • 成人难治性心脏骤停患者(纳入经济评价的研究人群)。

研究设计与关键结果

  • 系统综述纳入15项经济评价研究,评估ECPR与标准治疗相比在成人难治性心脏骤停中的成本效益。
  • 12项(80%)报告ECPR具有成本效益的概率高,1项(7%)报告概率低,1项(7%)提示可能具有成本效益,1项(7%)认为无成本效益可能。
  • 报告无成本效益可能的研究专门评估急性主动脉夹层患者。
  • 调整后ICER范围为2,564至276,307美元;采用美国支付意愿阈值(150,000美元)时10项研究显示ECPR仍具成本效益,采用替代阈值(40,000美元)时7项研究仍具成本效益。

证据类型、等级与局限

  • 证据类型:系统综述(PROSPERO注册号CRD42024582408),纳入15项经济评价研究。
  • 质量评估使用Evers清单、Philips清单和CHEERS清单。
  • 所有报告成本换算为2025年美元以助比较。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为ECPR在某些场景下可能具有成本效益,但各研究间成本效益结果差异显著,反映方法学、生存假设和支付意愿阈值不同。
  • 作者指出经济评价异质性大,亟需标准化报告以指导ECPR在不同医疗场景中的实施。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Extracorporeal cardiopulmonary resuscitation (ECPR) is increasingly used for refractory cardiac arrest across the world, but its cost-effectiveness remains uncertain. We conducted this systematic review to assess the available date on the cost-effectiveness of ECPR compared with the standard care in patients with cardiac arrest.

METHODS: We searched MEDLINE ALL (Ovid), EMBASE (Ovid), the Tufts Cost-Effectiveness Analysis (CEA) registry, and the Web of Science databases from database inception to 3rd February 2025 for all economic evaluations that reported the cost-effectiveness of ECPR for refractory cardiac arrest in adults. We undertook backward and forward citation tracking to identify any additional relevant articles. We used the Evers checklist, Philips checklist, and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist to assess the quality of the included study and the completeness of reporting. All reported costs were translated into 2025 US dollars (US$) to aid comparability.

RESULTS: We included 15 studies. Of these, 12 (80 %) reported a high probability of ECPR being cost-effective, 1 (7 %) reported a low probability, 1 (7 %) suggested ECPR was potentially cost-effective, and 1 (7 %) concluded no probability of cost-effectiveness. Notably, the latter study specifically evaluated ECPR in patients with acute aortic dissection. The adjusted incremental cost-effectiveness ratios (ICERs) ranged from $2,564 to $276,307. When using these ICERs, ECPR remained cost-effective in 10 studies using the US willingness to pay threshold ($150,000), and in 7 studies using alternative thresholds ($40,000).

CONCLUSION: ECPR may be cost-effective in some settings, but there is marked variability in the reported cost-effectiveness of ECPR across current studies. This reflects differences in methodology, survival assumptions, and willingness to pay thresholds. Economic evaluation for appropriate implementation of ECPR across various healthcare settings remains heterogenous, highlighting the imminent need for standardised reporting in this domain.

REVIEW REGISTRATION: PROSPERO (CRD42024582408).

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Alenazi A, Alotaibi B, Madan J, et al. The cost-effectiveness of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest: A systematic review. Resuscitation. 2025. PMID: 40967395. doi:10.1016/j.resuscitation.2025.110822

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。